IP Library Granted Patent US 10,959,946
Granted Patent B2
US 10,959,946 · App. 15/126,059 · Granted Mar 30, 2021

Composition and method for vancomycin oral liquid

Inventors: Indu Muni (North Reading, MA); Peter Mione (Malden, MA); Anisa Gandhi (Medford, MA); Cristina LeChiara (Saugus, MA)
Assignee: Azurity Pharmaceuticals, Inc.
A61K9/08A23L2/52A23L2/56A23L2/60A61K9/0095A61K38/14A61K47/12A61K47/26A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,959,946
App. No.
15/126,059
Granted
Mar 30, 2021
Kind
B2
Abstract

The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Claims (24)

1. A non-sterile stable liquid formulation formulated for oral administration, consisting of:

(a) 0.1-0.4% w/v anhydrous citric acid,

(b) water,

(c) 0.1-0.3% w/v sucralose,

(d) 0.01-0.1% w/v of a flavoring agent,

(e) 0.08-0.2% w/v sodium benzoate, and

(f) vancomycin hydrochloride,

wherein the non-sterile stable liquid formulation is a compounded solution of vancomycin hydrochloride that is homogenous and stable for at least 30 days at ambient and refrigerated temperature, and wherein the compounded solution has a high solubility in water and a pH of 2.5-4.5.

2. A liquid solution consisting of:

(a) 0.1-0.4% w/v anhydrous citric acid,

(b) water,

(c) 0.1-0.3% w/v sucralose,

(d) 0.01-0.1% w/v of a flavoring agent,

(e) 0.08-0.2% w/v sodium benzoate, and

(f) vancomycin hydrochloride, and

wherein the liquid solution is formulated for oral administration, homogenous, and stable for at least 30 days at ambient and refrigerated temperature.

3. The liquid solution of claim 2 , wherein the anhydrous citric acid is 0.12% w/v of the liquid solution.

4. The liquid solution of claim 2 , wherein the sucralose is 0.2% w/v of the liquid solution.

5. The liquid solution of claim 2 , wherein the flavoring agent is artificial grape flavor and wherein the artificial grape flavor is 0.05% w/v of the liquid solution.

6. The liquid solution of claim 2 , wherein the sodium benzoate is 0.1% w/v of the liquid solution.

7. The non-sterile stable liquid formulation of claim 1 , wherein the anhydrous citric acid is 0.12% w/v of the liquid formulation.

8. The non-sterile stable liquid formulation of claim 1 , wherein the sucralose is 0.2% w/v of the liquid formulation.

9. The non-sterile stable liquid formulation of claim 1 , wherein the flavoring agent is artificial grape flavor and wherein the artificial grape flavor is 0.05% w/v of the liquid formulation.

10. The non-sterile stable liquid formulation of claim 1 , wherein the sodium benzoate is 0.1% w/v of the liquid formulation.

Assignments (12)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 049209, FRAME 0272 Recorded Jun 24, 2025
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: CUTISPHARMA, INC. (N/K/A AZURITY PHARMACEUTICALS, INC.)
Reel/Frame 071704/0458 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
SECURITY INTEREST Recorded Sep 20, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057532/0424 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 057531/0403 →
SECURITY INTEREST Recorded Apr 16, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055938/0859 →
CHANGE OF NAME Recorded Apr 9, 2020
From: CUTISPHARMA, INC.
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 052351/0891 →
RELEASE OF SECURITY INTEREST Recorded May 17, 2019
From: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
To: CUTISPHARMA, INC.
Reel/Frame 049212/0549 →
SECURITY INTEREST Recorded May 17, 2019
From: CUTISPHARMA, INC.; SILVERGATE PHARMACEUTICALS, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 049209/0272 →
SECURITY INTEREST Recorded Mar 21, 2018
From: CUTISPHARMA, INC.
To: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
Reel/Frame 045300/0385 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE MISSPELLING OF INVENTOR NAME PREVIOUSLY RECORDED AT REEL: 041268 FRAME: 0247. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 29, 2017
From: MUNI, INDU; MIONE, PETER; GANDHI, ANISA; LECHIARA, CRISTINA
To: CUTISPHARMA, INC.
Reel/Frame 042108/0659 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2017
From: MUNI, INDU; MIONE, PETER; GANDHI, ANISA; LECHIARA, CHRISTINA
To: CUTISPHARMA, INC.
Reel/Frame 041268/0247 →
Continuity (3)
Provisional Application 61953076 · Mar 14, 2014
Provisional Application 61992414 · May 13, 2014
Related Publication 20170079910A1 · Mar 23, 2017